Visser H K
Ned Tijdschr Geneeskd. 2004 May 8;148(19):916-8.
An advisory report on vaccination against pertussis by the National Vaccination Programme Review Committee of the Health Council of the Netherlands makes recommendations on improving pertussis vaccination in the Netherlands. Since 1996, between 4000 and 8000 cases of pertussis have been reported each year, mainly in young children who have already been vaccinated. The main cause of this increase, apart from decreasing immunity in older children and adults, seems to be diminished vaccine effectiveness due to the occurrence of non-vaccine related strains of the pertussis bacterium in the Netherlands. The cellular vaccine used in the Netherlands contains low levels of the major antigens pertussis toxin and pertactin. The Health Council recommends the fastest possible transition to the use of an acellular combination vaccine. Such a vaccine will be effective and will have considerably fewer side effects than the one currently in use. The Committee recommends that research is done into the sources of pertussis infections in young infants.
荷兰卫生理事会国家疫苗接种计划审查委员会发布的一份关于百日咳疫苗接种的咨询报告,就改善荷兰的百日咳疫苗接种提出了建议。自1996年以来,每年报告的百日咳病例在4000至8000例之间,主要发生在已经接种过疫苗的幼儿身上。除了大龄儿童和成人免疫力下降之外,这种病例增加的主要原因似乎是由于荷兰出现了与疫苗无关的百日咳杆菌菌株,导致疫苗效力降低。荷兰使用的细胞疫苗中主要抗原百日咳毒素和丝状血凝素的含量较低。卫生理事会建议尽快过渡到使用无细胞联合疫苗。这种疫苗将是有效的,并且与目前使用的疫苗相比副作用要少得多。委员会建议对幼儿百日咳感染的来源进行研究。